Hormon reseptör pozitif, HER-2 negatif metastatik meme kanserli hastalarda CDK4/6 inhibitörü tedavisi öncesi sistemik immün inflamasyon indekslerinin ve prognostik nutrisyonel indeksin prognostik önemi

Abstract

Amaç: Sistemik inflamatuvar indeksler ve Prognostik nutrisyonel indeks birçok tümör tipinde kötü prognoz ile ilişkilidir. Çalışmamızda hormon reseptörü pozitif HER2 negatif metastatik meme kanserli hastalarda CDK4/6 inhibitörü tedavisi öncesinde sistemik inflamatuar indeksi, prognostik nutrisyonel indeks, Nötrofil/Lenfosit oranı, Platelet/Lenfosit oranı, Lenfosit Monosit Oranı, C-reaktif protein/albümin oranı, sistemik inflamatuar yanıt indeksi gibi belirteçlerin progresyonsuz sağkalım ve tüm sağkalım üzerine etkisini araştırdık. Gereç ve yöntem: Ocak 2018-Mayıs 2022 tarihleri arasında Tıbbi Onkoloji polikliniğe başvuran hormon reseptörü pozitif HER2 negatif metastatik meme kanserli hastalarda CDK4/6 inhibitörü tedavisi öncesi hastaların verileri retrospektif olarak incelendi. Bu belirteçlerin progresyonsuz sağkalım ve total sağkalım üzerine etkisi araştırıldı. Bulgular: Çalışmaya 79 hasta dahil edildi. Hastaların ortanca yaşları 53 (aralık 26-80 yıl) idi. Yetmiş hasta (%88,6) postmenopozaldı. Hastaların 68’inin (%86,1) performans skoru 0‘dı. Adjuvan endokrin tedavi sırasında 10 hastanın (%12,7) metastazı gelişti. PSK’yi etkileyen faktörler; yaş <50 (p=0,061), adjuvan endokrin tedavi sırasında metastaz gelişmesi (p=0,09) ve C-reaktif protein/albümin oranı (p=0,019) iken; TSK’ı etkileyen faktörler; yaş <50 (p=0,069) ve adjuvan endokrin tedavi sırasında metastaz gelişmesi (p=0,012) olarak bulundu. Sonuç: Hormon reseptörü+/HER2 – metastatik meme kanserli hastalarda CDK4/6 inhibitörü tedavisinden önce hastaların sistemik inflamatuvar indeksleri ve prognostik nutrisyonel indeksi progresyonsuz sağkalımı etkilemektedir. Ayrıca hastalarda adjuvan endokrin tedavi sırasında metastaz gelişmesi, progesteron reseptör yüzdesi ve 50 yaşın altı olması tüm sağkalım için olumsuz prognostik faktörler olarak değerlendirildi.

Keywords

• HR+/Her2- meme kanseri
• CDK4/6 inhibitörü
• sistemik inflamatuar indeksler
• prognostik nutrisyonel indeks
• PSK

Prognostic significance of systemic immune inflammation indices and prognostic nutritional index before CDK4/6 inhibitor therapy in hormone receptor positive, HER2 negative metastatic breast cancer patients

Abstract

Purpose: As systemic inflammatory indices and prognostic nutritional index are associated with poor prognosis in many tumor types, the goal of the present study was to ascertain their effect along with the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte ratio, C-reactive protein/albumin ratio, and systemic inflammatory response index on the progression-free survival (PFS) and overall survival (OS) of hormone receptor-positive HER2-negative (HR+/HER2−) metastatic breast cancer patients before CDK4/6 inhibitor treatment. Materials and methods: The medical records of 79 patients with HR+/HER2− metastatic breast cancer who presented at the Medical Oncology Outpatient Clinic between January 2018 and May 2022 were retrospectively analyzed to gather relevant data measured before CDK4/6 inhibitor treatment in order to establish the effect of key markers on their PFS and OS. Results: The median age of the participating patients, 70 (88.6%) of whom were postmenopausal, was 53 years (range 26-80 years). While 68 patients (86.1%) had a 0 performance score, 10 (12.7%) developed metastases during adjuvant endocrine therapy. Factors affecting PFS were age <50 (p=0.061), metastasis development during adjuvant endocrine therapy (p=0.09) and C-reactive protein/albumin ratio (p=0.019), while OS was primarily influenced by age <50 (p=0.069) and metastasis development during adjuvant endocrine therapy (p=0.012). Conclusion: In the examined HR+/HER2− metastatic breast cancer patients, systemic inflammatory indices and prognostic nutritional index before CDK4/6 inhibitor treatment affected PFS. In addition, metastasis development during adjuvant endocrine therapy, progesterone receptor percentage, and age below 50 years emerged as prognostic factors for shorter overall survival.

Keywords

• HR+/HER2− metastatic breast cancer
• CDK4/6 inhibitors
• systemic inflammatory indices
• prognostic nutritional index
• PFS

References

1. 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-249. https://doi.org/10.3322/caac.21660
2. 2. Harbeck N, Gnant M. Breast cancer. Lancet 2017;389:1134-1150. https://doi.org/10.1016/S0140-6736(16)31891-8
3. 3. Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:691-722. https://doi.org/10.6004/jnccn.2022.0030
4. 4. Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021;32:1475-1495. https://doi.org/10.1016/j.annonc.2021.09.019
5. 5. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:1979-1987. https://doi.org/10.1158/1078-0432.CCR-09-1823
6. 6. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-1783. https://doi.org/10.1200/JCO.2005.03.768
7. 7. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Ann Oncol 2018;29:1541-1547. https://doi.org/10.1093/annonc/mdy155
8. 8. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-439. https://doi.org/10.1016/S1470-2045(15)00613-0

9. 9. Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35:3638-3646. https://doi.org/10.1200/JCO.2017.75.6155 10. Stoiber D, Assinger A. Platelet-leukocyte interplay in cancer development and progression. Cells 2020;9:855. https://doi.org/10.3390/cells9040855
10. 11. Hu B, Yang XR, Xu Y, et al. Systemic Immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 2014;20:6212-6222. https://doi.org/10.1158/1078-0432.CCR-14-0442
11. 12. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124. https://doi.org/10.1093/jnci/dju124
12. 13. Li B, Zhou P, Liu Y, et al. Platelet-to-lymphocyte ratio in advanced Cancer: Review and meta-analysis. Clin Chim Acta 2018;483:48-56. https://doi.org/10.1016/j.cca.2018.04.023
13. 14. Wu M, Guo J, Guo L, Zuo Q. The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer. Tumour Biol 2016;37:12525-12533. https://doi.org/10.1007/s13277-016-5122-y 15. Sun L, Hu W, Liu M, et al. High systemic ınflammation response ındex (SIRI) ındicates poor outcome in gallbladder cancer patients with surgical resection:a single ınstitution experience in China. Cancer Res Treat 2020;52:1199-1210. https://doi.org/10.4143/crt.2020.303
14. 16. Okadome K, Baba Y, Yagi T, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer. Ann Surg 2020;271:693-700. https://doi.org/10.1097/SLA.0000000000002985
15. 17. Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 2017;19:2. https://doi.org/10.1186/s13058-016-0794-1
16. 18. Hu RJ, Liu Q, Ma JY, Zhou J, Liu G. Preoperative lymphocyte-to-monocyte ratio predicts breast cancer outcome:a meta-analysis. Clin Chim Acta 2018;484:1-6. https://doi.org/10.1016/j.cca.2018.05.031
17. 19. Chen L, Bai P, Kong X, et al. Prognostic nutritional index (PNI) in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator. Front Cell Dev Biol 2021;9:656741. https://doi.org/10.3389/fcell.2021.656741
18. 20. Wang Y, Li Y, Chen P, Xu W, Wu Y, Che G. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis. Ann Transl Med 2019;7:433. https://doi.org/10.21037/atm.2019.08.116
19. 21. Zhang Y, Xiao G, Wang R. Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer:a meta-analysis. Cancer Manag Res 2019;11:4185-4200. https://doi.org/10.2147/CMAR.S190006
20. 22. Zhong JH, Huang DH, Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors:a systematic review and meta-analysis. Oncotarget 2017;8:75381-75388. https://doi.org/10.18632/oncotarget.18856
21. 23. Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers:a meta-analysis. World J Surg Oncol 2020;18:197. https://doi.org/10.1186/s12957-020-01974-w
22. 24. Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. J Cell Mol Med 2020;24:2993-3021. https://doi.org/10.1111/jcmm.14934
23. 25. Wei L, Xie H, Yan P. Prognostic value of the systemic inflammation response index in human malignancy:a meta-analysis. Medicine (Baltimore). 2020;99:e23486. https://doi.org/10.1097/MD.0000000000023486
24. 26. Zhang Y, Liu F, Wang Y. Evidence of the prognostic value of pretreatment systemic inflammation response index in cancer patients: a pooled analysis of 19 cohort studies. Dis Markers 2020;2020:8854267. https://doi.org/10.1155/2020/8854267
25. 27. Hua X, Long ZQ, Huang X, et al. The preoperative systemic inflammation response index (SIRI) independently predicts survival in postmenopausal women with breast cancer. Curr Probl Cancer 2020;44:100560. https://doi.org/10.1016/j.currproblcancer.2020.100560
26. 28. Jiang C, Zhang S, Qiao K, Xiu Y, Yu X, Huang Y. The pretreatment systemic inflammation response index as a useful prognostic factor is better than lymphocyte to monocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy. Clin Breast Cancer 2022;22:424-438. https://doi.org/10.1016/j.clbc.2022.03.003
27. 29. Mohri Y, Inoue Y, Tanaka K, Hiro J, Uchida K, Kusunoki M. Prognostic nutritional index predicts postoperative outcome in colorectal cancer. World J Surg 2013;37:2688-2692. https://doi.org/10.1007/s00268-013-2156-9
28. 30. Sun J, Wang D, Mei Y, et al. Value of the prognostic nutritional index in advanced gastric cancer treated with preoperative chemotherapy. J Surg Res 2017;209:37-44. https://doi.org/10.1016/j.jss.2016.09.050
29. 31. Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma:the prognostic nutritional index (PNI). Br J Cancer 2012;106:1439-1445. https://doi.org/10.1038/bjc.2012.92
30. 32. Hua X, Long ZQ, Huang X, et al. The value of prognostic nutritional index (PNI) in predicting survival and guiding radiotherapy of patients with T1-2N1 breast cancer. Front Oncol 2020;9:1562. https://doi.org/10.3389/fonc.2019.01562
31. 33. Zhu M, Chen L, Kong X, et al. The systemic inflammation response index as an independent predictor of survival in breast cancer patients: a retrospective study. Front Mol Biosci 2022;9:856064. https://doi.org/10.3389/fmolb.2022.856064
32. 34. Anwar SL, Cahyono R, Avanti WS, Budiman HY, Harahap WA, Aryandono T. Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression:a retrospective cohort study. Ann Med Surg (Lond) 2021;63:102144. https://doi.org/10.1016/j.amsu.2021.01.092
33. 35. Guo S, He X, Chen Q, et al. The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients. BMC Cancer 2017;17:171. https://doi.org/10.1186/s12885-017-3119-6
34. 36. Wang Y, Xiao X, Wang T, et al. A survival model in locally advanced and metastatic pancreatic ductal adenocarcinoma. J Cancer 2018;9:1301-1307. https://doi.org/10.7150/jca.23984
35. 37. Zhu M, Ma Z, Zhang X, et al. C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis. BMC Med 2022;20:301. https://doi.org/10.1186/s12916-022-02506-x
36. 38. Zhou L, Ma S, Balde AI, Han S, Cai Z, Li Z. A retrospective propensity score matched study of the preoperative C-reactive protein to albumin ratio and prognosis in patients with resectable non-metastatic breast cancer. Med Sci Monit 2019;25:4342-4352. https://doi.org/10.12659/MSM.913684
37. 39. Zhang Z, Lin Q, Chen Y, et al. Prognostic evaluation of metastasis-related lymphocyte/monocyte ratio in stage Ⅰ-Ⅲ breast cancer receiving chemotherapy. Front Oncol 2022;11:782383. https://doi.org/10.3389/fonc.2021.782383
38. 40. Fribbens C, O'Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 2016;34:2961-2968. https://doi.org/10.1200/JCO.2016.67.3061
39. 41. Luqmani YA, Alam Eldin N. Overcoming resistance to endocrine therapy in breast cancer: new approaches to a nagging problem. Med Princ Pract 2016;25:28-40. https://doi.org/10.1159/000444451
40. 42. Grasic Kuhar C, Bracko M, Zakotnik B. Risk factors for late relapse and death in patients with early breast cancer. Neoplasma 2008;55:416-420.